Correction to ‘Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real-world clinical setting’

IF 3.2 2区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

ESC Heart Failure Pub Date : 2025-01-17 DOI:10.1002/ehf2.15211

{"title":"Correction to ‘Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real-world clinical setting’","authors":"","doi":"10.1002/ehf2.15211","DOIUrl":null,"url":null,"abstract":"\n Nordberg Backelin, C., Fu, M., and Ljungman, C. (2020) Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real-world clinical setting. ESC Heart Failure, 7: 1049–1055. 10.1002/ehf2.12644.In the abstract, in the last sentence of methods and results, the text ‘Female gender [odds ratio (OR) 3.58; 95% CI 1.07–2.00; P = 0.038] and NT-proBNP ≥ median level (OR 0.48; 95% CI 0.26–0.90; P = 0.021) was associated with termination of the medication’ was incorrect. This should have read ‘Female gender [odds ratio (OR) 3.58; 95% CI 1.07–2.00; P = 0.038] was associated with termination of the medication’.Also, in page 1051, in the last paragraph of the results, the text ‘Age-adjusted logistic regression analysis showed that female gender (OR 3.58; 95% CI 1.07–2.00; P = 0.038) and a NT-proBNP higher than the median level of 2,860 ng/L (OR 0.48; 95% CI 0.26–0.90; P = 0.021) predicted discontinuation of the treatment’ was wrong. This should have read ‘Age-adjusted logistic regression analysis showed that female gender (OR 3.58; 95% CI 1.07–2.00; P = 0.038) predicted discontinuation of the treatment’.We apologize for this error.","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":"12 2","pages":"1525"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ehf2.15211","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESC Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ehf2.15211","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Nordberg Backelin, C., Fu, M., and Ljungman, C. (2020) Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real-world clinical setting. ESC Heart Failure, 7: 1049–1055. 10.1002/ehf2.12644.

In the abstract, in the last sentence of methods and results, the text ‘Female gender [odds ratio (OR) 3.58; 95% CI 1.07–2.00; P = 0.038] and NT-proBNP ≥ median level (OR 0.48; 95% CI 0.26–0.90; P = 0.021) was associated with termination of the medication’ was incorrect. This should have read ‘Female gender [odds ratio (OR) 3.58; 95% CI 1.07–2.00; P = 0.038] was associated with termination of the medication’.

Also, in page 1051, in the last paragraph of the results, the text ‘Age-adjusted logistic regression analysis showed that female gender (OR 3.58; 95% CI 1.07–2.00; P = 0.038) and a NT-proBNP higher than the median level of 2,860 ng/L (OR 0.48; 95% CI 0.26–0.90; P = 0.021) predicted discontinuation of the treatment’ was wrong. This should have read ‘Age-adjusted logistic regression analysis showed that female gender (OR 3.58; 95% CI 1.07–2.00; P = 0.038) predicted discontinuation of the treatment’.

We apologize for this error.

查看原文本刊更多论文

更正“在现实世界的临床环境中，沙克比利-缬沙坦治疗心力衰竭伴射血分数降低的早期经验”。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ESC Heart Failure Medicine-Cardiology and Cardiovascular Medicine

CiteScore

7.00

自引率

7.90%

发文量

461

审稿时长

12 weeks

期刊介绍： ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.